Lee Krug

Lee Krug at Memorial Sloan Kettering led or co-led the CHECKMATE-743 phase III trial establishing nivolumab plus ipilimumab as a first-line standard of care for unresectable pleural mesothelioma, the most significant advance in mesothelioma treatment in nearly two decades. His research on the immunobiology of mesothelioma has contributed to understanding mechanisms of response and resistance to checkpoint inhibition. He has been central to multiple mesothelioma clinical trials at MSK and has contributed to understanding second-line treatment options. His translational work on mesothelioma immune microenvironment has shaped immunotherapy development.